Publication: Expression of the activation markers Blimp1, Foxp1 and pStat3 in extranodal diffuse large B-cell lymphomas
Authors
Petrakis, Georgios ; Kostopoulos, Ioannis ; Venizelos, Ioannis ; Lambropoulou, Maria ; Vouras, Kyriakos ; Vakalopoulou, Sofia ; Mandala, Eudokia ; Tsatalas, Constantinos ; Papadopoulos, Nicolas
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia. Departamento de Biología Celular e Histología
publication.page.editor
publication.page.department
DOI
DOI: 10.14670/HH-11-852
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Different studies have suggested that the
expression of biomarkers related to lymphoid cell
activation may provide information on the behavior of
DLBCL. Most studies have concentrated on nodal or a
mixture of nodal and extranodal lymphomas. The
differential expression and potential clinical impact of
these markers in a homogeneous group of extranodal
DLBCLs are not well defined. In this study, we
investigated the expression of three activation markers,
Blimp1, Foxp1 and pStat3, in a cohort of 35 extranodal
DLBCLs homogeneously treated with R-CHOP.
Immunohistochemical stains were evaluated using an
immunoreactivity score on representative paraffin
sections. Blimp1 was positive in 55% (19/35), Foxp1 in
60% (21/35), and pStat3 in 69% (24/35) of our cases.
We did not observe any statistical differences in the
expression of these markers in GCB and non-GCB
tumors or in gastrointestinal and non-gastrointestinal
tumors. Blimp1 expression was negatively correlated
with overall survival (OS) (p=0.001) in the whole series
and in the non-GCB group (Muris algorithm) (p=0.002).
Foxp1 positivity and pStat3 positivity had no impact on
the outcome of the patients in the global cohort, but they
were associated with a better survival in the non-GCB
subgroup (p=0.033, p=0.044 respectively). Multivariate
analysis showed that Blimp1 expression but not COO
was an independent negative prognostic factor for OS
(HR=17.5, 95%, CI=2.2-141.1, p=0.007). Our results
suggest that these markers are differentially expressed
and have different impacts on outcome in extranodal
DLBCLs compared to nodal tumors, emphasizing the
need to evaluate separately these and probably other
markers in these subsets of tumors.
publication.page.subject
Citation
Histology and Histopathology, Vol.32, nº8, (2017)
item.page.embargo
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/